ICER update to pricing models of remdesivir for COVID-19.
出版信息
PharmacoEcon Outcomes News. 2020;857(1):2. doi: 10.1007/s40274-020-6939-6. Epub 2020 Jul 11.
Abstract
摘要
相似文献
1
ICER update to pricing models of remdesivir for COVID-19.针对COVID-19的瑞德西韦定价模型的ICER更新。
PharmacoEcon Outcomes News. 2020;857(1):2. doi: 10.1007/s40274-020-6939-6. Epub 2020 Jul 11.
2
ICER's second update to pricing models of remdesivir for COVID-19.
PharmacoEcon Outcomes News. 2020;867(1):2. doi: 10.1007/s40274-020-7299-y. Epub 2020 Nov 28.
3
The journey of remdesivir: from Ebola to COVID-19.瑞德西韦的历程：从埃博拉到新冠病毒。
Drugs Context. 2020 May 22;9. doi: 10.7573/dic.2020-4-14. eCollection 2020.
4
ICER releases pricing models for potential COVID-19 treatments.
PharmacoEcon Outcomes News. 2020;853(1):1. doi: 10.1007/s40274-020-6796-3. Epub 2020 May 16.
5
Value-based differential pricing: efficient prices for drugs in a global context.基于价值的差异化定价：全球背景下的药品有效定价
Health Econ. 2015 Mar;24(3):294-301. doi: 10.1002/hec.3021. Epub 2013 Dec 11.
6
COVID-19 and Advanced Practice Registered Nurses: Frontline Update.2019冠状病毒病与高级执业注册护士：一线最新情况
J Nurse Pract. 2020 Sep;16(8):551-555. doi: 10.1016/j.nurpra.2020.06.014. Epub 2020 Jun 18.
引用本文的文献
1
Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.巴瑞替尼与标准治疗相比的成本效益：美国 COVID-19 住院患者的建模研究。
Clin Ther. 2021 Nov;43(11):1877-1893.e4. doi: 10.1016/j.clinthera.2021.09.016. Epub 2021 Oct 4.
Zotero 插件